Boehringer furthers inflammatory expansion with €407M biobucks bet on Immunitas asset
Boehringer Ingelheim has put up 407.5 million euros in biobucks to secure global rights to a first‑in‑class antibody Immunitas Therapeutics is developing for ch...
Boehringer Ingelheim has put up 407.5 million euros in biobucks to secure global rights to a first‑in‑class antibody Immunitas Therapeutics is developing for chronic inflammatory and autoimmune diseases.